Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J Lafitte

Showing results (131-140 of 152) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|July 3, 2003
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysisB Martin, M Paesmans, T Berghmans, et al.
The European Respiratory Journal|May 31, 2011
Validation and comparison of several published prognostic systems for patients with small cell lung cancerM Paesmans, J J Lafitte, J Lecomte, et al.
The Journal of Allergy and Clinical Immunology|January 12, 2000
IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthmaA Shimbara, P Christodoulopoulos, A Soussi-Gounni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
The Journal of Allergy and Clinical Immunology|April 11, 2001
Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseasesD Miotto, P Christodoulopoulos, R Olivenstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J Thiriaux, et al.
British Journal of Cancer|October 12, 2000
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancerJ P Sculier, J J Lafitte, M Paesmans, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J Thiriaux, et al.
British Journal of Cancer|December 17, 2008
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerM J McKeage, J Von Pawel, M Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2013
Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective studyT Berghmans, L Ameye, L Willems, et al.
Pageof 16

Showing results (131-140 of 152) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|July 3, 2003
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysisB Martin, M Paesmans, T Berghmans, et al.
The European Respiratory Journal|May 31, 2011
Validation and comparison of several published prognostic systems for patients with small cell lung cancerM Paesmans, J J Lafitte, J Lecomte, et al.
The Journal of Allergy and Clinical Immunology|January 12, 2000
IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthmaA Shimbara, P Christodoulopoulos, A Soussi-Gounni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
The Journal of Allergy and Clinical Immunology|April 11, 2001
Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseasesD Miotto, P Christodoulopoulos, R Olivenstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J Thiriaux, et al.
British Journal of Cancer|October 12, 2000
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancerJ P Sculier, J J Lafitte, M Paesmans, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, J Thiriaux, et al.
British Journal of Cancer|December 17, 2008
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerM J McKeage, J Von Pawel, M Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2013
Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective studyT Berghmans, L Ameye, L Willems, et al.
Pageof 16